4BIO Capital portfolio company ADC Therapeutics SA closes an upsized IPO of over $267.6 million

4BIO Capital publishes review of AAV gene therapies in Cell & Gene Therapy Insights

4BIO Capital leads Redpin Therapeutics’ $15.5 million Series A

4BIO Capital appoints Philippe Fauchet, OBE, as Venture Partner, Japan

4BIO Capital raises $50 million in first close of new advanced therapies fund

Spark Therapeutics enters into definitive merger agreement with Roche